Suraj Muley, MD
Neurology · Phoenix, AZNPI 1417056730
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,184,682 of the $1,713,043 with a category attached, or 69.2%. 22 manufacturers reported payments, led by AstraZeneca at 27.1% of the total. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,884 payments — averaging $909.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$464K
- CSL Behring$359K
- Argenx US, Inc.$190K
- Takeda Pharmaceuticals U.S.A., Inc.$169K
- Grifols USA, LLC$153K
- UCB, Inc.$129K
- plus $250K from 16 others
Across 95 payments — averaging $11,478 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$626K
- UCB SA$181K
- Sanofi$106K
- Argenx US, Inc.$52K
- Takeda Pharmaceuticals U.S.A., Inc.$42K
- AstraZeneca$36K
- plus $47K from 3 others
What the payments were for
- Consulting fees$303,38718%
- Speaking & faculty fees$1,184,68269%
- Travel & lodging$181,02411%
- Food & beverage$43,7253%
- Education$2250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 503 | $463,660 |
| CSL Behring | 444 | $359,388 |
| Argenx US, Inc. | 219 | $189,768 |
| Takeda Pharmaceuticals U.S.A., Inc. | 193 | $169,065 |
| Grifols USA, LLC | 109 | $152,530 |
| UCB, Inc. | 177 | $129,021 |
| Amgen(2 entities) | 68 | $67,602 |
| Johnson & Johnson | 37 | $52,386 |
| UCB SA | 8 | $52,160 |
| Catalyst Pharmaceuticals, Inc. | 31 | $25,213 |
| Shire North American Group Inc | 29 | $17,322 |
| Grifols Shared Services North America, Inc. | 19 | $12,619 |
| Octapharma USA, Inc. | 17 | $10,387 |
| Sanofi | 2 | $7,536 |
| Janssen Scientific Affairs, LLC | 5 | $1,606 |
| Biogen | 9 | $918 |
| Janssen Global Services, LLC | 1 | $688 |
| Genentech, Inc. | 5 | $414 |
| Bristol Myers Squibb | 3 | $341 |
| EMD Serono, Inc. | 3 | $218 |
| AbbVie | 1 | $124 |
| Banner Life Sciences, LLC | 1 | $78 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hizentra$351,157
- SOLIRIS$211,470
- ULTOMIRIS$189,626
- Gamunex-C$156,848
- VYVGART$152,083
- Rystiggo$137,963
- HYQVIA$76,266
- GAMMAGARD LIQUID$63,117
- UPLIZNA$40,487
- VYVGART HYTRULO$31,255
- FIRDAPSE$24,937
- Zilbrysq$21,088
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$8,237
- Xembify$7,177
- Privigen$6,380
- BKEMV$4,273
- PANZYGA$2,000
- ZEPOSIA$341
- EVRYSDI$262
- Vumerity$252
How this compares
$1,713,043 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UltomirisRavulizumab-Cwvz | 24 | $1,639,027 |
| FirdapseAmifampridine Phosphate | 23 | $1,024,864 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 58 | $836,695 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 56 | $808,679 |
| SolirisEculizumab | 12 | $612,834 |
| VyvgartEfgartigimod Alfa-Fcab | 11 | $587,172 |
| HyqviaIgg/Hyaluronidase,recombinant | 21 | $371,745 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 22 | $330,281 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 20 | $236,049 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 19 | $128,572 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $128,154 |
| Mycophenolate Mofetil | 66 | $8,602 |
| Pyridostigmine Bromide | 109 | $7,912 |
| Prednisone | 350 | $2,606 |
| Gabapentin | 87 | $2,016 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaUltomiris, Soliris | $463,660 | $2,251,86036 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $25,213 | $1,024,86423 claims |
| CSL BehringPrivigen | $359,388 | $808,67956 claims |
| Argenx US, Inc.Vyvgart | $189,768 | $587,17211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia, Gammagard Liquid | $169,065 | $499,90033 claims |
| Grifols USA, LLCGamunex-C | $152,530 | $128,57219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Phoenix
- Barry HendinPhoenix$2.3M
- Maria OspinaPhoenix$2.1M
- Eric ErossPhoenix$778K
- Steve ChungPhoenix$685K
- Marwan SabbaghPhoenix$603K
- Kerry KnievelPhoenix$509K
- Lori TravisPhoenix$406K
- Jeffrey GittPhoenix$275K
- Todd SchwedtPhoenix$273K
- Joshua TobinPhoenix$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.